Michael Lobritz

Michael Lobritz, MD, PhD is Global Head of the Infectious Diseases therapeutic area at F. Hoffmann La-Roche, Ltd (Roche), where he oversees a division responsible for the discovery and early clinical development of novel antibiotics and antivirals. Founded in 1896 in Basel, Switzerland, Roche has grown into the world’s largest biotechnology company and global leader in in vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. Michael also serves on committees and boards focused on the challenges of antimicrobial resistance (AMR) and infectious diseases, including the AMR Industry Alliance and AMR Action Fund. Prior to joining Roche in 2017, Michael was attending physician in medicine and infectious diseases at Massachusetts General Hospital and Instructor in Medicine at Harvard Medical School, both in Boston, USA. He is a Fellow of the Infectious Diseases Society of America.